Vernalis extends cancer research collaboration with Novartis Institutes for BioMedical Research
Joint research and development programme on Hsp90, a target implicated in a number of different cancers - Vernalis to receive a $1.5 million signature fee - Novartis to make an investment in new Vernalis shares of approximately ?5 million
Vernalis plc announces that the Novartis Institutes for BioMedical Research, Inc., (Novartis) has exercised its option to license exclusive worldwide rights to Vernalis' lead oncology research programme on Hsp90. Today's announcement is the positive conclusion of the option agreement the companies signed in December 2003.
The companies will conduct a joint research programme under which Novartis will provide research funding to Vernalis over an initial three-year period. In addition, Novartis is responsible for funding and conducting the preclinical and clinical development of product candidates, and for commercialisation.
Novartis will pay Vernalis a signature fee of $1.5 million and a series of further payments upon achievement of development milestones for each product candidate that Novartis takes into development. Vernalis will also receive royalties on commercial sales of collaboration products. In addition, Novartis will make an equity investment of approximately ?5 million ($9 million) through the subscription for 7,106,344 new Vernalis ordinary shares at 70.18p per share, representing almost 4.6% percent of Vernalis' enlarged issued share capital. The methodology for calculating the subscription price was established at the time of entering the option agreement in December 2003.
In the event that two product candidates from the collaboration reach the market, total payments to Vernalis from Novartis could exceed $75 million, excluding royalties.
The Vernalis Hsp90 programme is the result of a collaboration established in March 2002 with Cancer Research Technology Ltd (CRT) [formerly Cancer Research Ventures Ltd] and The Institute of Cancer Research, under which Vernalis will pay CRT and The Institute of Cancer Research a proportion of its revenues from the agreement with Novartis.
Simon Sturge, chief executive officer of Vernalis said, "I am delighted to be announcing a third major deal for Vernalis in only six weeks. Novartis is a world leader in oncology and an optimal partner to help maximise the opportunity for developing Hsp90 inhibitors as potential cancer treatments. This collaboration further validates Vernalis' research capability and provides additional funding."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
